Tango Therapeutics, Inc. (NASDAQ:TNGX - Get Free Report) hit a new 52-week high on Thursday . The company traded as high as $10.00 and last traded at $8.37, with a volume of 6986037 shares traded. The stock had previously closed at $8.66.
Analyst Upgrades and Downgrades
A number of equities analysts have weighed in on TNGX shares. Weiss Ratings reissued a "sell (e+)" rating on shares of Tango Therapeutics in a research report on Wednesday, October 8th. Guggenheim upped their target price on Tango Therapeutics from $8.00 to $10.00 and gave the company a "buy" rating in a research report on Wednesday, August 6th. Finally, Piper Sandler began coverage on Tango Therapeutics in a research report on Monday, August 18th. They issued an "overweight" rating and a $11.00 target price on the stock. Five analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $10.50.
Check Out Our Latest Report on TNGX
Tango Therapeutics Price Performance
The firm has a 50-day moving average price of $7.48 and a 200 day moving average price of $5.07. The company has a market cap of $901.87 million, a price-to-earnings ratio of -6.29 and a beta of 1.67.
Tango Therapeutics (NASDAQ:TNGX - Get Free Report) last issued its quarterly earnings results on Tuesday, August 5th. The company reported ($0.35) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.35). The business had revenue of $3.18 million during the quarter, compared to analysts' expectations of $6.41 million. Tango Therapeutics had a negative return on equity of 79.72% and a negative net margin of 599.11%. On average, equities analysts anticipate that Tango Therapeutics, Inc. will post -1.19 EPS for the current fiscal year.
Insider Activity
In other Tango Therapeutics news, major shareholder Rock Ventures Iv L.P. Third sold 500,000 shares of the company's stock in a transaction on Thursday, September 25th. The stock was sold at an average price of $8.02, for a total transaction of $4,010,000.00. Following the completion of the sale, the insider directly owned 13,863,975 shares in the company, valued at $111,189,079.50. This represents a 3.48% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Insiders sold 2,995,100 shares of company stock valued at $21,504,700 in the last three months. Insiders own 7.50% of the company's stock.
Institutional Inflows and Outflows
A number of large investors have recently modified their holdings of TNGX. Adage Capital Partners GP L.L.C. bought a new position in shares of Tango Therapeutics in the 2nd quarter valued at $30,235,000. Commodore Capital LP bought a new position in shares of Tango Therapeutics in the 2nd quarter valued at $7,680,000. Soleus Capital Management L.P. bought a new position in shares of Tango Therapeutics in the 2nd quarter valued at $3,738,000. Candriam S.C.A. bought a new position in shares of Tango Therapeutics in the 2nd quarter valued at $3,629,000. Finally, Vivo Capital LLC bought a new position in shares of Tango Therapeutics in the 2nd quarter valued at $3,072,000. 78.99% of the stock is currently owned by institutional investors.
About Tango Therapeutics
(
Get Free Report)
Tango Therapeutics, Inc, a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions.
See Also
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Tango Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Tango Therapeutics wasn't on the list.
While Tango Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
